Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AC Immune inks neuro-focused deal with Essex Bio-Technology
July 2017
SHARING OPTIONS:

LAUSANNE, Switzerland & HONG KONG—AC Immune SA has launched a research collaboration agreement with Essex Bio-Technology Ltd. for the preclinical and clinical co-development of a novel biological therapeutic for treating neurodegenerative diseases and neuroinflammation. The collaboration will focus on the development of a recombinant protein therapeutic candidate that acts on a neuroprotective mechanism to treat neurological diseases. Essex will provide AC Immune with joint research commitment and financial support for the pre-IND development, and the companies will create a joint clinical development and commercial strategy for a potential product. No financial details were released.
 
Prof. Andrea Pfeifer, CEO of AC Immune, noted that this gives the company “its first R&D base in Asia with potential new development opportunities in that region,” and added that “The collaboration is a natural progression for our two companies who know each other very well, Essex Bio-Technology being a significant shareholder of AC Immune.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.